Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2020Journal of Clinical and Translational ResearchOpen Access

High pre-procedural platelet/lymphocyte ratio predicts no-reflow after primary PCI in STEMI.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Coronary no-reflow phenomenon in STEMI is linked to poor outcomes and involves deregulated inflammation, prompting investigation into the relationship between platelet/lymphocyte ratio and no-reflow after PPCI.

Does pre-procedural platelet/lymphocyte ratio predict the no-reflow phenomenon in patients with acute STEMI treated with primary PCI?

Population

200 patients with STEMI undergoing PPCI

Comparison

Pre-procedural platelet/lymphocyte ratio levels

Key result

A high pre-procedural platelet/lymphocyte ratio independently predicted the no-reflow phenomenon following primary percutaneous coronary intervention in patients with acute STEMI.

Authors

HBHala Mahfouz BadranCardiac ImagingAFAhmed FatahKing Fahd University of Petroleum and MineralsGSGhada SoltanMenoufia University

Discussion

Loading...

Member takes

Overview

May aid pre-PCI risk stratification in STEMI; hypothesis-generating and requires prospective validation.

Study Design

Type

Cross-Sectional (n=200)

Multicenter

Yes

Structured PICO

Does pre-procedural platelet/lymphocyte ratio predict the no-reflow phenomenon in patients with acute STEMI treated with primary PCI?

P
Population
200 patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI)
I
Intervention
Pre-procedural platelet/lymphocyte ratio (PLR)
O
Outcome
No-reflow phenomenon (defined as coronary blood flow thrombolysis in myocardial infarction grade ≤II)surrogate

Main Result

Effect estimate: β -0.485 (95% CI -0.006-0.001)

p-value: p=<0.002

High pre-procedural platelet/lymphocyte ratio is an independent predictor of reperfusion failure (no-reflow) in STEMI patients undergoing primary PCI.

Limitations

  • Small sample size
  • No patient follow-up to examine the occurrence of adverse cardiac events
  • Other inflammatory markers such as endothelin 1 and thromboxane A2 were not measured
  • Lack of standardized definition of no-reflow across studies
  • Limited clinical application of PLR as it is not routinely measured before PPCI

Cite This Study

Badran et al. (2020) conducted a cross-sectional in ST-segment elevation myocardial infarction (STEMI) (n=200). Platelet/lymphocyte ratio (PLR) was evaluated on No-reflow phenomenon (TIMI flow grade ≤II) (β -0.485, 95% CI -0.006-0.001, p=<0.002). A high pre-procedural platelet/lymphocyte ratio independently predicted the no-reflow phenomenon following primary percutaneous coronary intervention in patients with acute STEMI.

synapsesocial.com/papers/6a0f378e28dd8f49a2bdc858https://doi.org/10.18053/jctres.06.202001.004
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Value of Platelet to Lymphocytes Ratio in Predicting Angiographic Reflow after Primary Percutaneous Coronary Intervention in STEMI Patient2019
  2. 2Platelet‐Lymphocyte ratio is a predictor for the development of no‐reflow phenomenon in patients with ST‐segment elevation myocardial infarction after thrombus aspiration2021 · 15 citations
  3. 3The Utility the Platelet-to-Lymphocyte Ratio in Predicting Angiographic Reflow after Primary Percutaneous Coronary Intervention in Patients with Acute ST- Segment Elevation Myocardial Infarction2018
  4. 4The Utility of the Platelet–Lymphocyte Ratio for Predicting No Reflow in Patients With ST-Segment Elevation Myocardial Infarction2014 · 101 citations
  5. 5Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention2014 · 49 citations